How big is Scilex Holding Co.?

As of Jun 18, Scilex Holding Co. has a market capitalization of 310.97 million and reported net sales of 50.71 million with a net profit of -74.51 million over the latest four quarters. The balance sheet shows shareholder's funds of -192.64 million and total assets of 92.95 million.

As of Jun 18, Scilex Holding Co. has a market capitalization of 310.97 million, classified as a Micro Cap.<BR><BR>As of Jun 18, the company reported net sales of 50.71 million for the latest four quarters, while the net profit for the same period was -74.51 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -192.64 million and total assets of 92.95 million.

What does Scilex Holding Co. do?

Scilex Holding Co. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $5 million and a net loss of $26 million as of March 2025. It has a market cap of $310.97 million and key metrics indicating it is currently loss-making with no dividend yield.

Overview:<BR>Scilex Holding Co. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 310.97 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.20 <BR>Return on Equity: 46.46% <BR>Price to Book: -1.47 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Scilex Holding Co.?

Is Scilex Holding Co. overvalued or undervalued?

As of May 12, 2023, Scilex Holding Co. is considered risky and overvalued due to negative financial metrics, including a P/B ratio of -2.00 and an EV/EBITDA of -5.15, alongside a year-to-date stock performance of -66.63%, significantly underperforming the S&P 500's 2.44%.

As of 12 May 2023, the valuation grade for Scilex Holding Co. has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company appears to be overvalued given its current metrics, particularly with a P/E ratio that is not applicable due to losses, a Price to Book Value of -2.00, and an EV to EBITDA of -5.15. These ratios suggest that the company is struggling to generate positive returns relative to its capital employed.<BR><BR>In comparison to its peers, Scilex Holding Co. has a notably worse EV to EBITDA ratio than Akebia Therapeutics, Inc. at 95.1122 and Praxis Precision Medicines, Inc. at -2.3991, both of which also carry a risky valuation. The stark contrast in these metrics highlights the challenges Scilex faces within its industry. Furthermore, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -66.63% compared to the index's 2.44%. This reinforces the notion that Scilex is currently overvalued in the market.

Is Scilex Holding Co. technically bullish or bearish?

As of September 5, 2025, Scilex Holding Co. is in a bullish trend supported by strong technical indicators, having outperformed the S&P 500 recently, despite a one-year decline of 27.41%.

As of 5 September 2025, the technical trend for Scilex Holding Co. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and the weekly MACD and KST are also bullish, indicating positive momentum. The weekly OBV is bullish, further confirming the strength of the trend. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show mixed signals with a mildly bullish weekly stance and a mildly bearish monthly stance. <BR><BR>In terms of performance, Scilex has outperformed the S&P 500 over the past week and month, with returns of 1.18% and 32.4% respectively, compared to the S&P 500's returns of 1.05% and 2.33%. However, the one-year return shows a decline of 27.41%, while the S&P 500 gained 17.14%. Overall, the current bullish trend is supported by strong technical indicators, despite some mixed signals in longer time frames.